Business Context and Reporting Period
Company: Aprea Therapeutics, Inc. (APRE)
Filing Type: Form 8-K (Current Report)
Date: October 23, 2024
Context: The filing discloses a Regulation FD event regarding the presentation of preliminary safety results for the Company's WEE1 inhibitor, APR-1051, at the EORTC-NCI-AACR Symposium in Barcelona, Spain.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary update is the dissemination of clinical data regarding the APR-1051 candidate.
Guidance, Outlook, and Risks
- Management Commentary: The Company highlighted preliminary safety results for APR-1051 in a poster presentation at a major oncology symposium.
- Outlook: No specific financial guidance or operational outlook is provided in this filing.
- Risks and Contingencies: The filing notes that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the specific data points in the press release.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed safety data on APR-1051.
- Confirm the specific findings presented at the EORTC-NCI-AACR Symposium.
- Review the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not contain financial data.